Approaches for the development of drugs for treatment of obesity and metabolic syndrome

Current Pharmaceutical Design

Volumn 22, Issue 7, 2016, Pages 895-903

  Maksimov, Maksim L ^a   Svistunov, Andrey A ^a   Tarasov, Vadim V ^a   Chubarev, Vladimir N ^a   Ávila Rodriguez, Marco ^b   Barreto, George E ^b,c   Dralova, Olga V ^a   Aliev, Gjumrakch ^d,e,f,g  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^d GALLY International Biomedical Research Consulting LLC   (United States)

^e University of Atlanta   (United States)

^f INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^g GALLY International Biomedical Research Institute Inc   (United States)

Author keywords

Adipokines; Beloranib; Contrave ; Empatic ; Liraglutide; Lorcaserin; Orlistat; Pharmacotherapy of obesity; Qsymia; Rimonabant; Sibutramine; Tesofensine; Treatment of obesity and ms

Indexed keywords

AGENTS AFFECTING METABOLISM; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTIOBESITY AGENT; BELORANIB; EXENDIN 4; FLUOXETINE; LIRAGLUTIDE; LORCASERIN; METFORMIN PLUS SITAGLIPTIN; METRELEPTIN; NALTREXONE; NORADRENALIN; PANCREAS ENZYME; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SEROTONIN; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ENERGY METABOLISM; HUMAN; LIFE EXPECTANCY; LIPID ABSORPTION; MEDICAL PRACTICE; METABOLIC SYNDROME X; MORBID OBESITY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; STOMACH SECRETION; WEIGHT REDUCTION; ANIMAL; BODY MASS; COMPLICATION; DRUG POTENTIATION; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTI-OBESITY AGENTS; BODY MASS INDEX; DRUG DESIGN; DRUG SYNERGISM; HUMANS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 84958531487     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151209153047     Document Type: Article

References (114)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
3. Wilson JD, Foster DW, Kronenberg HM, Reed P, Williams L. Textbook of Endocrinology. Philadelphia: Saunders 1998.
4. Obesity O. Update OECD Health Statistics 2014.
5. Excellence NIfHaC. Obesity: guidance on the prevention, identication, assessment and management of overweight and obesity in adults and children: quick reference guide 1: for local authorities, schools and early years providers, workplaces and the public. USA: NIH 2006.
6. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K, Clinical Efficacy Assessment Subcommittee of the American College of P. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525-31.
7. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113-9.
8. WHO. 10 facts on obesity. 2014.
9. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007; 176: S1-13.
10. WHO. Global Health Risks: mortality and burden of disease attributable to selected major risks 2009. 2011.
11. WHO. Obesity and overweight Fact sheet No. 311. 2011.
12. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63: 2985-3023.
13. Authors/Task Force M, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-87.
14. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-7.
15. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002; 288: 2709-16.
16. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16: 235-51.
17. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8.
18. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesityassociated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14.
19. Mule G, Nardi E, Cottone S, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257: 503-13.
20. Schillaci G, Pirro M, Vaudo G, et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1078-82.
21. Cuspidi C, Meani S, Fusi V, et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875-82.
22. Kawamoto R, Tomita H, Oka Y, Kodama A, Kamitani A. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232-8.
23. Cuspidi C, Meani S, Valerio C, et al. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. J Hypertens 2005; 23: 1589-95.
24. Guideline NPH. Prevention of cardiovascular disease - Guidance on the prevention of cardiovascular disease at the population level. 2010.
25. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000; 404: 672-7.
26. National Heart LaBI. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. national institutes of health. Obes Res 1998; 6 (Suppl 2): 51S-209S.
27. Clinical NIfHa. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children: quick reference guide 2 [home page on the Internet]. 2006.
28. Dalton S. Overweight and weight management. The health professional’s guide to understanding and practice. Aspen Publishers 1997.
29. Laaksonen DE, Lindstrom J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005; 54: 158-65.
30. National Heart L, and Blood Institute and North American Association for the Study of Obesity. Practical guide on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health 2000.
31. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012; 125: 1695-703.
32. Rescrire. Medicinal products used in weight control. 2012.
33. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? Diabetes Care 2008; 31 (Suppl 2): S269-77.
34. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-7.
35. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA. Combined drug treatment of obesity. Obes Res 1995; 3 (Suppl 4): 497S-500S.
36. Grundy SM, Hansen B, Smith SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
37. Patel KN, Joharapurkar AA, Patel V, et al. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Can J Physiol Pharmacol 2014; 92: 975-83.
38. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
39. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002; 95: 153-64.
40. Gamaleddin IH, Trigo JM, Gueye AB, et al. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front Psychiatry 2015; 6: 41.
41. Fang Q, Li FQ, Li YQ, et al. Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats. Pharmacol Biochem Behav 2011; 99: 738-42.
42. Li YW, Langdon S, Pieschl R, et al. Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats. Eur J Pharmacol 2014; 737: 47-56.
43. Biedermann F, Fleischhacker WW, Kemmler G, Ebenbichler CF, Lechleitner M, Hofer A. Sibutramine in the treatment of antipsychotic- induced weight gain: a pilot study in patients with schizophrenia. Int Clin Psychopharmacol 2014; 29: 181-4.
44. Franco RR, Cominato L, Damiani D. The effect of sibutramine on weight loss in obese adolescents. Arq Bras Endocrinol Metabol 2014; 58: 243-50.
45. (EMA) EMA. Questions and answers on the suspension of medicines containing sibutramine Outcome of a procedure under Article 107 of Directive 2001/83/EC6 August 2010 EMA/808179/2009 rev EMEA/H/A-107/1256 2010.
46. Sibutramine (Meridia) withdrawn. Med Lett Drugs Ther 2010; 52: 88.
47. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340: c824.
48. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995; 35: 1103-8.
49. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
50. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced- energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005; 7: 699-708.
51. Wirth A. Reduction of body weight and co-morbidities by orlistat: the XXL--primary health care trial. Diabetes Obes Metab 2005; 7: 21-7.
52. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002; 22: 814-22.
53. da Silva AI, Braz GR, Pedroza AA, et al. Fluoxetine induces lean phenotype in rat by increasing the brown/white adipose tissue ratio and UCP1 expression. J Bioenerg Biomembr 2015; 47(4): 309-18.
54. Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 2015; 17(11): 1021-32.
55. Yanovski SZ, Yanovski JA. Naltrexone extended-release plus bupropion extended-release for treatment of obesity. JAMA 2015; 313: 1213-4.
56. Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2006; 60: 347-51.
57. Al-Barazanji K, McNulty J, Binz J, et al. Synergistic Effects of a GPR119 agonist with metformin on weight loss in diet-induced obese mice. J Pharmacol Exp Ther 2015; 353: 496-504.
58. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22.
59. Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: A systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10: e0126769.
60. Sheikh Mea. Energy balance in subclinical hypothyroidism: no predisposition to obesity Diabetes Obes Metab 1999; 23: 82.
61. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S109-12.
62. Iepsen EW, Lundgren J, Dirksen C, et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond) 2015; 39: 834-41.
63. Finan B, Clemmensen C, Muller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 2015; 418: 42-54.
64. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010; 6: 255-69.
65. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv 2005; 5: 282-91.
66. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014; 84: 1-11.
67. Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008; 6: 338-43.
68. Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65: 577-83.
69. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008; 16: 1363-9.
70. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1906-13.
71. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010; 88: 69-78.
72. Doggrell SA. Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13. Expert Opin Investig Drugs 2009; 18: 1043-6.
73. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-33.
74. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008; 325: 577-87.
75. Pipelinereview.com. Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone. 2008.
76. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo- controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-56.
77. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2: 911-22.
78. Lorcaserin. In obesity: unacceptable risks. Prescrire Int 2014; 23: 117-20.
79. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009; 10: 1069-81.
80. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustainedrelease/ bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Develop Ther 2014; 8: 1419-27.
81. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17: 30-9.
82. Klein S, Wadden T, Erickson J, Kim Dea. Naltrexone+bupropion combination causes significant weight loss without worsening psychiatric symptoms. Proceedings of 69th Annual Scientific Sessions of the American Diabetes Association: New Orleans, Louisiana, USA 2009; pp. 1730.
83. Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother 2015; 16: 1263-74.
84. Marmura MJ. Safety of topiramate for treating migraines. Expert Opin Drug Saf 2014; 13: 1241-7.
85. Liang CS, Yang FW, Huang SY, Ho PS. Continuing weight-loss effect after topiramate discontinuation in obese persons with schizophrenia: a pilot open-label study. Pharmacopsychiatry 2014; 47: 162-8.
86. Singh J, Kumar R. Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res 2015; 5: 157-8.
87. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-42.
88. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1: 106-16.
89. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled- release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
90. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
91. Kiortsis DN. A review of the metabolic effects of controlledrelease Phentermine/Topiramate. Hormones (Athens) 2013; 12: 507-16.
92. Bluher M. Clinical relevance of adipokines. Diabetes Metab J 2012; 36: 317-27.
93. Bluher M. Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab 2014; 3: 230-40.
94. Bauche IB, El Mkadem SA, Pottier AM, et al. Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology 2007; 148: 1539-49.
95. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatinproducing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003; 144: 544-51.
96. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
97. Savage DB, O'Rahilly S. Leptin: a novel therapeutic role in lipodystrophy. J Clin Invest 2002; 109: 1285-6.
98. Chou K, Perry CM. Metreleptin: first global approval. Drugs 2013; 73: 989-97.
99. Muller TD, Sullivan LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 2012; 18: 383-93.
100. Amylin Pharmaceuticals ITPCL. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program. 2011.
101. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-26.
102. Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clin Pharmacol Ther 2009; 86: 592-5.
103. Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013; 503: 493-9.
104. Lotfy M, Singh J, Kalasz H, Tekes K, Adeghate E. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J 2011; 5: 82-92.
105. Oh IS, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12.
106. Kloting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucoselowering effects. Diabetologia 2011; 54: 1819-23.
107. Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 2009; 58: 1526-31.
108. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105.
109. Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans. PLoS One 2013; 8: e73680.
110. Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene? Nature 2012; 488: E9-10; discussion E10-1.
111. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221: T1-16.
112. Nordisk N. Medication Guide Saxenda 2014.
113. Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab 2015; 17: 566-72.
114. Drug Discovery Development. Phase 2 Results on Zafgen's Weight-Loss Drug Beloranib Released: Zafgen Inc 2013.